These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30946552)

  • 1. A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.
    Gellad WF; Ennis M; Kuza CC
    N Engl J Med; 2019 May; 380(18):1688-1690. PubMed ID: 30946552
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
    Rubin R
    JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
    [No Abstract]   [Full Text] [Related]  

  • 3. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
    [No Abstract]   [Full Text] [Related]  

  • 5. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
    Dickson S; Reynolds I
    JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending.
    Dusetzina SB; Conti RM; Yu NL; Bach PB
    JAMA Intern Med; 2017 Aug; 177(8):1185-1188. PubMed ID: 28558108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
    Dusetzina SB; Bach PB
    JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
    [No Abstract]   [Full Text] [Related]  

  • 8. Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):825-827. PubMed ID: 31711137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who benefits from drug discounts? Drugmakers, hospitals battle over indigent-care program.
    Lee J
    Mod Healthc; 2013 Jul; 43(28):8-9. PubMed ID: 24044228
    [No Abstract]   [Full Text] [Related]  

  • 10. CMS retreats on Part D rule intended to reduce drug costs and improve access.
    Dickson V
    Mod Healthc; 2014 Mar; 44(11):10. PubMed ID: 24830094
    [No Abstract]   [Full Text] [Related]  

  • 11. Recommendations for Lowering Prescription Drug Spending in Public Programs.
    Jazowski SA; Dusetzina SB
    Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
    [No Abstract]   [Full Text] [Related]  

  • 12. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
    Hayford TB
    JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Top 40 Medicare Part D prescription drugs Ranked by total payments in 2014.
    Mod Healthc; 2016 Oct; 46(36):42. PubMed ID: 30398720
    [No Abstract]   [Full Text] [Related]  

  • 15. It's time to bail out seniors trapped in the Medicare donut hole!
    Dalen JE
    Am J Med; 2009 Jul; 122(7):595-6. PubMed ID: 19559156
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: Medicare Part D.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
    [No Abstract]   [Full Text] [Related]  

  • 17. Remember the MaineRx.
    Kemp R
    Appl Health Econ Health Policy; 2014 Feb; 12(1):1-5. PubMed ID: 24420789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017.
    Hwang TJ; Dusetzina SB; Feng J; Maini L; Kesselheim AS
    JAMA; 2019 Jul; 322(3):267-269. PubMed ID: 31310287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulating Drug Prices while Increasing Innovation.
    Conti RM; Frank RG; Gruber J
    N Engl J Med; 2021 Nov; 385(21):1921-1923. PubMed ID: 34767322
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates.
    Kakani P; Kyle MA; Chandra A; Maini L
    Health Aff (Millwood); 2024 Oct; 43(10):1420-1427. PubMed ID: 39374459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.